40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC
Title:
40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC
Author:
Stintzing, S. Müller-Huesmann, H. Heyde, E. von der Virchow, I. Greil, R. Kisro, J. Stübs, P. Buerkle, D. Distelrath, A. Wierecky, J. Wein, A. Gerger, A. Arnold, D. Fritsch, R.M. Hegewisch-Becker, S. Vogel, A. Wagner, A.D. Winder, T. Koeberle, D. Prager, G.